See termination reason in detailed description.

This will be the first clinical study of the development of PHA-794428 in a pediatric population. Since differences in PK and/or PD response may occur between adult and pediatric subjects, it is deemed appropriate to first conduct an exploratory single dose study in pediatric patients to assess safety and tolerability in this patient population. In addition this will add pediatric data to facilitate the prediction of the optimal therapeutic dose to be tested in repeated dose phase 2b trials in children, using PK/PD modeling

The study terminated on 10-Dec-2007. Pfizer's decision to terminate the program was due to cases of injection-site lipoatrophy that were reported in the clinical Phase 2 studies after a single injection of PHA 794428.

Inclusion Criteria:

• 1.Male and female children with a minimum age of 6 years
• 2. Prepubertal as defined by Tanner staging
• 3. Growth hormone deficiency

Exclusion Criteria:

• 1. PGHD patients with uncontrolled pituitary tumor growth
• 2. Tumors within 3 mm of the optic chiasm
• 3. Serum ALT and/or AST >= 1.5 times the upper limit of normal range